Status:

COMPLETED

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Lead Sponsor:

Kala Pharmaceuticals, Inc.

Conditions:

Dry Eye Syndromes

Keratoconjunctivitis Sicca

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of d...

Detailed Description

This is a Phase II, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle...

Eligibility Criteria

Inclusion

  • • Have a documented clinical diagnosis of dry eye disease in both eyes

Exclusion

  • Known hypersensitivity/contraindication to study product(s) or components.
  • History of glaucoma, IOP \>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.
  • Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening.
  • In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

Key Trial Info

Start Date :

June 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2015

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT02188160

Start Date

June 1 2014

End Date

March 1 2015

Last Update

January 6 2021

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Sall Research Medical Center

Artesia, California, United States, 90701

2

North Valley Eye Medical Group

Mission Hills, California, United States, 91345

3

Martel Eye Medical Group

Rancho Cordova, California, United States, 95670

4

Eye Center of Southern CT, P.C.

Hamden, Connecticut, United States, 06518

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | DecenTrialz